| OXY |
Report |
Adjusted diluted EPS |
BEAT |
pred $1.95 vs. cons $1.89 |
MEDIUM |
| OXY |
Report |
Upstream production |
IN-LINE |
pred 1.414 MMboe/d vs. cons 1.416 MMboe/d |
MEDIUM |
| OXY |
Report |
Free cash flow |
MISS |
pred $2.45B vs. cons $2.54B |
MEDIUM |
| OXY |
Guide |
FY26 production (FY26) |
UNCHANGED |
guide 1.44 MMboe/d vs. cons 1.426 MMboe/d |
MEDIUM |
| OXY |
Guide |
Q3 production (Q3 2026) |
UNCHANGED |
guide 1.44 MMboe/d vs. cons 1.445 MMboe/d |
LOW |
| OXY |
Guide |
FY26 total capital (FY26) |
UNCHANGED |
guide $5.5B-$5.9B vs. cons UNVERIFIED |
LOW |
| OXY |
Guide |
FY26 midstream pretax income (FY26) |
UNCHANGED |
guide ~$1.1B vs. cons UNVERIFIED |
LOW |
| OXY |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
LOW |
| OXY |
Return |
5-day cumulative residual |
-2.0% (STABILIZE) |
STABILIZE — maintained FY framework limits follow-through after the initial Archetype-C de-rating |
LOW |